Pancreatic Cancer Research

ResearcherCleveland ClinicActive in the last 2 years

Robert C.G. Martin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5537-3387; OpenAlex author ID A5069026924. Sources: ClinicalTrials.gov.

Their work

Papers
67 (first author 5, last author 29)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
125
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 2 papers · 2014: 4 papers · 2015: 7 papers · 2016: 6 papers, 1 trial · 2017: 4 papers, 1 trial · 2018: 1 paper, 1 trial · 2019: 5 papers · 2020: 3 papers · 2021: 4 papers · 2022: 4 papers · 2023: 3 papers · 2024: 5 papers · 2025: 8 papers · 2026: 5 papers

Papers 50 of 67

  1. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. Co-author DOI 10.1093/oncolo/oyag416↗
  2. Evaluation of radiomics and radiologic signatures for diagnosis and clinical outcomes in pancreatic adenocarcinoma and pancreatic neuroendocrine: A pilot study. Co-author DOI 10.1177/18758592261455545↗
  3. Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine. Last author DOI 10.1186/s12967-025-07596-8↗
  4. Chemotherapy Completion as a Quality Metric in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers18121912↗
  5. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353144↗
  6. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  7. What Is the Role of Irreversible Electroporation for Pancreatic Cancer? Co-author DOI 10.1016/j.yasu.2025.04.011↗
  8. Scanxiety in survivors of pancreatic cancer. Last author DOI 10.1080/07347332.2024.2408552↗
  9. Irreversible Electroporation and Beta-Glucan-Induced Trained Innate Immunity for Treatment of Pancreatic Ductal Adenocarcinoma: A Phase II Study. Co-author DOI 10.1097/xcs.0000000000001291↗
  10. Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-024-16742-3↗
  11. Detection of Exhaled Volatile Organic Compounds as Noninvasive Biomarkers for Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-17685-z↗
  12. Surgical Outcomes in Stage IV Pancreatic Cancer with Liver Metastasis Current Evidence and Future Directions: A Systematic Review and Meta-Analysis of Surgical… Last author DOI 10.3390/cancers17040688↗
  13. Evaluation of Recurrence Risk in Irreversible Electroporation-Treated Pancreatic Adenocarcinoma Patients Using Radiomics Signatures. Last author DOI 10.3390/cancers17142338↗
  14. Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective. Last author DOI 10.1002/jso.27697↗
  15. Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer. Last author DOI 10.1016/j.surg.2023.08.042↗
  16. Diagnosis of Pancreatic Cancer after Cholecystectomy in the Elderly. Co-author DOI 10.1177/00031348241227165↗
  17. Effectiveness and Safety of Irreversible Electroporation When Used for the Ablation of Stage 3 Pancreatic Adenocarcinoma: Initial Results from the DIRECT Regis… Co-author DOI 10.3390/cancers16233894↗
  18. Optimization of Exocrine Pancreatic Insufficiency in Pancreatic Adenocarcinoma Patients. Last author DOI 10.3390/nu16203499↗
  19. Infection reporting in patients undergoing irreversible electroporation of locally advanced pancreatic cancer. First author DOI 10.1002/jso.27310↗
  20. Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer. Co-author DOI 10.1016/j.surg.2022.07.033↗
  21. Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2022-006221↗
  22. Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cti2.1430↗
  23. Locally advanced pancreatic cancer: a reliable contraindication to resection in the modern era? Last author DOI 10.1016/j.hpb.2021.09.002↗
  24. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Co-author DOI 10.1038/s41467-022-28407-4↗
  25. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  26. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic ad… Last author DOI 10.1186/s12885-021-08474-4↗
  27. The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Last author DOI 10.1245/s10434-021-09662-z↗
  28. An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era. Last author DOI 10.1245/s10434-021-10174-z↗
  29. Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. Last author DOI 10.3389/fonc.2021.817220↗
  30. Safety, Efficacy, and Technical Details of Endoscopic Retrograde Cholangiopancreatography After Irreversible Electroporation for Locally Advanced Pancreatic Ca… Co-author DOI 10.1007/s11605-019-04223-y↗
  31. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2020.04.057↗
  32. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-020-08782-2↗
  33. Quality of life assessment for patients undergoing irreversible electroporation (IRE) for treatment of locally advanced pancreatic cancer (LAPC). Last author DOI 10.1016/j.amjsurg.2019.03.020↗
  34. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from … Last author DOI 10.1016/j.hpb.2018.12.004↗
  35. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  36. Post-treatment analysis of irreversible electroporation waveforms delivered to human pancreatic cancer patients. First author DOI 10.1109/embc.2019.8857259↗
  37. Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-018-07144-3↗
  38. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2018.01.037↗
  39. Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. Co-author DOI 10.1002/jso.24640↗
  40. Intra-operative navigation of a 3-dimensional needle localization system for precision of irreversible electroporation needles in locally advanced pancreatic c… Last author DOI 10.1016/j.ejso.2016.09.009↗
  41. Efficacy of preoperative immunonutrition in locally advanced pancreatic cancer undergoing irreversible electroporation (IRE). Co-author DOI 10.1016/j.ejso.2017.01.002↗
  42. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Co-author DOI 10.1245/s10434-017-5900-9↗
  43. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  44. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. Last author DOI 10.1002/jso.24288↗
  45. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. Co-author DOI 10.1002/jso.24404↗
  46. Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer. Last author DOI 10.1007/s00261-016-0815-7↗
  47. An update on the role of irreversible electroporation in locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2016.07.007↗
  48. Management of Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.suc.2016.07.010↗
  49. A cost analysis of a pancreatic cancer screening protocol in high-risk populations. First author DOI 10.1016/j.amjsurg.2014.11.017↗
  50. High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. First author DOI 10.1016/j.jss.2014.06.046↗

Trials 3

  1. Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Principal investigator NCT03484299↗
  2. Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Principal investigator NCT03080974↗
  3. American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry Principal investigator NCT02674100↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles Raben Scoggins · 20 shared papers, 2011–2026 · strength 2.68
  2. Prejesh Philips · 12 shared papers, 2014–2026 · strength 2.25
  3. Michael E. Egger · 9 shared papers, 2021–2026 · strength 2.05
  4. Jeremy Gaskins · 3 shared papers, 2025–2026 · strength 1.31
  5. Rebekah Ruth White · 6 shared papers, 2019–2026 · strength 1.21
  6. Marc W. Fromer · 5 shared papers, 2021–2026 · strength 1.08
  7. Chet W. Hammill · 4 shared papers, 2022–2026 · strength 0.87
  8. Jacob W. H. Gordon · 2 shared papers, 2025–2026 · strength 0.76
  9. Patricio Marcelo Polanco · 3 shared papers, 2024–2026 · strength 0.74
  10. Sean Patrick Cleary · 3 shared papers, 2024–2026 · strength 0.74
  11. Michael D. Kluger · 3 shared papers, 2024–2026 · strength 0.74
  12. Carlos H.F. Chan · 3 shared papers, 2024–2026 · strength 0.74
  13. Govindarajan Narayanan · 3 shared papers, 2021–2026 · strength 0.70
  14. Danial A. Malik · 2 shared papers, 2025–2026 · strength 0.63
  15. Syed Ameen Ahmad · 8 shared papers, 2011–2025 · strength 0.55
  16. Neal Bhutiani · 5 shared papers, 2016–2022 · strength 0.54
  17. David A. Iannitti · 3 shared papers, 2016–2026 · strength 0.54
  18. Christopher D. Wilson · 1 shared paper, 2025 · strength 0.54
  19. Nipun B. Merchant · 6 shared papers, 2012–2025 · strength 0.48
  20. Kyle R Stephens · 2 shared papers, 2024–2025 · strength 0.47
  21. Daniel Erik Abbott · 5 shared papers, 2014–2025 · strength 0.46
  22. Shishir Kumar Maithel · 5 shared papers, 2014–2025 · strength 0.46
  23. Noah Clements · 1 shared paper, 2025 · strength 0.42
  24. Matthew R. Woeste · 3 shared papers, 2021–2023 · strength 0.42
  25. Harshul Pandit · 4 shared papers, 2015–2022 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.